{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-058230","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.609666+00:00","generated_at":"2026-06-09T00:50:44.907966+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MindMed Q3 net loss $17.9M; cash $117.7M; Phase 2b GAD topline expected Q4 2023","bullets":["Cash and cash equivalents $117.7M at Sept 30, 2023; expected to fund operations into 2026.","Net loss $17.9M in Q3 2023 vs $16.5M in Q3 2022; R&D expenses rose to $13.2M from $7.8M.","Phase 2b study of MM-120 in GAD (198 participants) topline results expected in Q4 2023.","Phase 2a proof-of-concept study of MM-120 in ADHD (53 participants) topline data expected Q1 2024.","Initiation of Phase 1 study of MM-402 for ASD expected in Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-058230","json":"https://secwatch.observer/filing/0000950170-23-058230.json","markdown":"https://secwatch.observer/filing/0000950170-23-058230.md","text":"https://secwatch.observer/filing/0000950170-23-058230.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023058230/0000950170-23-058230-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023058230/mnmd-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:50:44.907966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e450b5c8badf5acf9fc9dd447c3786d38408d9ac","claim":"Definium Therapeutics, Inc. reported the quarter ended September 30, 2023 results: net income Net loss for the quarter ended September 30, 2023, was $17.9 million.","evidence_excerpt":"Net loss for the quarter ended September 30, 2023, was $17.9 million, compared to $16.5 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023058230/0000950170-23-058230-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss for the quarter ended September 30, 2023, was $17.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}